Literature DB >> 26837698

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

Saad Sirop Kenderian1, Thomas M Habermann1, William R Macon2, Kay M Ristow1, Stephen M Ansell1, Joseph P Colgan1, Patrick B Johnston1, David J Inwards1, Svetomir N Markovic1, Ivana N Micallef1, Carrie A Thompson1, Luis F Porrata1, James A Martenson3, Thomas E Witzig1, Grzegorz S Nowakowski1.   

Abstract

A number of reports have shown a propensity of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL). Long-term data on the incidence and outcomes of transformed NLPHL are lacking. A comprehensive analysis of the actively maintained Mayo Clinic Lymphoma Database was performed. Between 1970 and 2011, 222 consecutive adult patients with new untreated NLPHL were identified. Median age at diagnosis was 40 years, and 146 (66%) were males. The median follow-up was 16 years. Seventeen patients (7.6%) developed a transformation to DLBCL. The median time to transformation was 35 months (range, 6-268 months). Based on the observed 17 transformations during 2304 patient-years of follow-up, the rate of transformation was 0.74 per 100 patient-years. In a multivariate analysis, use of any prior chemotherapy ( ITALIC! P= .04) and splenic involvement ( ITALIC! P= .03) were significantly associated with increased risk of transformation. The 5-year overall survival (OS) in those with transformed disease was 76.4%, and transformation did not adversely affect OS when compared with patients who did not experience transformation. In this large single-institution cohort with long-term follow-up, the risk of transformation was lower than that observed in other low-grade lymphomas.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2016        PMID: 26837698      PMCID: PMC4841039          DOI: 10.1182/blood-2015-08-665505

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.

Authors:  James Z Huang; Dennis D Weisenburger; Julie M Vose; Timothy C Greiner; Patricia Aoun; Wing C Chan; James C Lynch; Philip J Bierman; James O Armitage
Journal:  Leuk Lymphoma       Date:  2004-08

2.  Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.

Authors:  C Jackson; B Sirohi; D Cunningham; A Horwich; K Thomas; A Wotherspoon
Journal:  Ann Oncol       Date:  2010-03-23       Impact factor: 32.976

3.  [Hodgkin disease with nodular lymphocytic predominance or type I (paragranuloma of Poppema-Lennert): a clinico-pathological entity. Study of 21 cases and review of the literature].

Authors:  V Meignin; J Briere; P Brice; C Gisselbrecht; P Gaulard; A Janin
Journal:  Ann Pathol       Date:  2000-01       Impact factor: 0.407

4.  Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.

Authors:  Irene Biasoli; Aspasia Stamatoullas; Véronique Meignin; Alain Delmer; Oumedaly Reman; Franck Morschhauser; Bertrand Coiffier; André Bosly; Marine Diviné; Pauline Brice
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

Review 5.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

6.  The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis.

Authors:  T Ohno; J Z Huang; G Wu; K H Park; D D Weisenburger; W C Chan
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

7.  Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.

Authors:  Ronald C Chen; Michael S Chin; Andrea K Ng; Yang Feng; Donna Neuberg; Barbara Silver; Geraldine S Pinkus; Mary Ann Stevenson; Peter M Mauch
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas.

Authors:  M Miettinen; K O Franssila; E Saxén
Journal:  Cancer       Date:  1983-06-15       Impact factor: 6.860

9.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Authors:  Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.

Authors:  Mubarak Al-Mansour; Joseph M Connors; Randy D Gascoyne; Brian Skinnider; Kerry J Savage
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

View more
  14 in total

Review 1.  Chimeric antigen receptor T cell therapies for acute myeloid leukemia.

Authors:  Bin Gu; Jianhong Chu; Depei Wu
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 2.  [Update on nodular lymphocyte predominant Hodgkin's lymphoma and related lesions].

Authors:  S Hartmann; M-L Hansmann
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

Review 3.  Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.

Authors:  Dennis A Eichenauer; Andreas Engert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Sven Borchmann; Erel Joffe; Craig H Moskowitz; Andrew D Zelenetz; Ariela Noy; Carol S Portlock; John F Gerecitano; Connie L Batlevi; Philip C Caron; Pamela Drullinsky; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Colette N Owens; M Lia Palomba; Anas Younes; David J Straus
Journal:  Blood       Date:  2019-02-15       Impact factor: 22.113

5.  Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Michelle A Fanale; Chan Yoon Cheah; Amy Rich; L Jeffrey Medeiros; Chao-Ming Lai; Yasuhiro Oki; Jorge E Romaguera; Luis E Fayad; F B Hagemeister; Felipe Samaniego; Maria A Rodriguez; Sattva S Neelapu; Hun J Lee; Loretta Nastoupil; Nathan H Fowler; Francesco Turturro; Jason R Westin; Michael L Wang; Peter McLaughlin; Chelsea C Pinnix; Sarah A Milgrom; Bouthaina Dabaja; Sandra B Horowitz; Anas Younes
Journal:  Blood       Date:  2017-05-18       Impact factor: 22.113

Review 6.  An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.

Authors:  Akira Satou; Taishi Takahara; Shigeo Nakamura
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

Review 7.  Hodgkin lymphoma: A review and update on recent progress.

Authors:  Satish Shanbhag; Richard F Ambinder
Journal:  CA Cancer J Clin       Date:  2017-12-01       Impact factor: 508.702

Review 8.  New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2016-06-13       Impact factor: 0.196

Review 9.  Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).

Authors:  Susanne Hofmann; Maria-Luisa Schubert; Lei Wang; Bailin He; Brigitte Neuber; Peter Dreger; Carsten Müller-Tidow; Michael Schmitt
Journal:  J Clin Med       Date:  2019-02-06       Impact factor: 4.241

10.  Analysis and impact of a multidisciplinary lymphoma virtual tumor board.

Authors:  Thomas M Habermann; Arushi Khurana; Ruth Lentz; John J Schmitz; Alexander G von Bormann; Jason R Young; Christopher H Hunt; Sara N Christofferson; Grzegorz S Nowakowski; Kristen B McCullough; Pedro Horna; Adam J Wood; William R Macon; Paul J Kurtin; Scott C Lester; Scott L Stafford; Ushrasree Chamarthy; Faraz Khan; Stephen M Ansell; Rebecca L King
Journal:  Leuk Lymphoma       Date:  2020-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.